Howard B. Rosen
Interim President and CEO

Sarvajna Dwivedi, PhD
Executive Vice President, R&D and Co-Founder

Colin Reisner, MD, FCCP, FAAAAI
Chief Medical Officer, and Executive Vice President of Clinical Development and Medical Affairs

Michael Golden
Vice President, Regulatory Affairs and Quality

William Picht, Jr.
Vice President, Finance and Administration

Chadwick J. Orevillo, MPH
Senior Director and Head of Clinical Operations

Howard B. Rosen

Interim President and CEO

Howard B. Rosen is currently interim President and CEO for Pearl Therapeutics and a consultant to several companies in the industry and a lecturer in the Department of Chemical Engineering at Stanford University. He previously served as Vice President, Commercial Strategy, at Gilead Sciences, Inc., where he was responsible for strategic marketing, global brand management, health economics, competitive intelligence, market research and Gilead's overall portfolio and business planning. Prior to Gilead, Mr. Rosen spent more than 10 years in various roles at ALZA Corporation, an operating company within the Johnson & Johnson Family of Companies, most recently as President of the ALZA division of Johnson & Johnson. During his tenure at ALZA, he was responsible for product development activities, portfolio management, corporate and new product planning, mergers and acquisitions, R&D planning and technology ventures.

Prior to ALZA, Mr. Rosen managed the west coast practice of Integral, Inc., served as Director of Corporate Development at GenPharm International, Inc., and was a consultant in the San Francisco office of McKinsey & Co. Mr. Rosen also serves on the Boards of Directors of AcelRx Pharmaceuticals, Inc., PaxVax, Inc. and CNS Therapeutics, Inc.

Mr. Rosen holds an M.B.A. from the Stanford Graduate School of Business, an M.S. in chemical engineering from the Massachusetts Institute of Technology, and a B.S. in chemical engineering from Stanford University. He is a member of the National Academy of Engineering.

Sarvajna Dwivedi, PhD

Executive Vice President, R&D and Co-Founder

Sarvajna Dwivedi has extensive experience in drug development at Glaxo, Dura, Alkermes, and Nektar. He was involved in the development of over 40 molecules in various therapeutic classes and dosage forms from discovery to commercialization. At Nektar, he was the Director of Product Development, responsible for new product identification, design, planning, and development efforts. At Alkermes, he was the Director of Delivery Systems, responsible for the engineering and development of inhalers for multiple products. At Dura, Dr. Dwivedi led and managed formulation design and development efforts for various Spiros programs. Earlier, at Glaxo, Dr. Dwivedi was involved in the development, manufacturing, and approval of Flovent® Diskhaler, Serevent® Diskus, Advair® Diskus, Relenza® Diskhaler, and Ventolin® Evohaler.

In addition to his product development experience, Dr. Dwivedi has led and conducted technical due diligence efforts for in-licensing, out-licensing and acquisition opportunities. Dr. Dwivedi holds MSc and PhD degrees in Pharmaceutical Sciences from the University of British Columbia, and M.Pharm. & B.Pharm.(Hons) from Banaras Hindu University in India.

Colin Reisner, MD, FCCP, FAAAAI

Chief Medical Officer, and Executive Vice President of Clinical Development and Medical Affairs

Colin Reisner joined Pearl Therapeutics in October 2007, in the capacity of Chief Medical Officer and Executive Vice President of Clinical Development and Medical Affairs. Dr. Reisner is responsible for all of Pearl’s clinical development activities including advancing Pearl’s lead program, a combination bronchodilator, through regulatory submission.

Dr. Reisner has significant experience in the development and commercialization of inhaled respiratory products. Prior to Pearl, he was Executive Director for Global Respiratory Development at Novartis responsible for both clinical development and shaping Novartis’ global strategy for respiratory products. Earlier at Novartis he was the Global Brand Medical Director for Xolair®, the first biologic agent approved for asthma. Prior to Novartis, Dr. Reisner served as Senior Director in the Respiratory Division at GlaxoSmithKline. There he played a key role in the development of market-leading inhaled respiratory products, focusing on Advair® in COPD, and on pediatric drug development. Dr. Reisner began his career in the pharmaceutical industry at Boehringer Ingelheim and worked on a wide variety of programs including Combivent® and on the Respimat® device.

Dr. Reisner graduated from the University of Witwatersrand Medical School in South Africa. He completed his training in Internal Medicine followed by fellowship training in Allergy and Immunology at National Jewish, Denver, Colorado, and was an assistant consulting professor of Allergy and Immunology at Yale University, and also at Duke University. Dr. Reisner is a Diplomat of the American Board of Internal Medicine and the American Board of Allergy and Immunology.

Michael Golden

Vice President, Regulatory Affairs and Quality

Michael Golden’s experience in the development of respiratory and pharmaceutical products spans over 25 years. Prior to joining Pearl he was at GlaxoSmithKline, where from 1988 he played significant roles in product development, regulatory submission and approval for 8 marketed orally inhaled and nasally delivered drugs including Flovent®, Advair®, Ventolin®, and Veramyst® Nasal Spray. Most recently he was the Director, External Advocacy, Global CMC Submissions, Regulatory Affairs at GSK. In this position he was the principal liaison between GSK and the FDA with regard to Quality by Design initiatives. Additionally, Mr. Golden was a board member of the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS), a member of the Drug Product Technical Committee of the Product Quality Research Institute (PQRI), and a member of the FDA Advisory Committee for Pharmaceutical Sciences sub-team on Delivered Dose Uniformity for orally inhaled and nasal drug products.

He began his career at GSK as a research investigator leading project teams and helping to establish the Inhalation Product Development group. Prior to joining GSK, Mr. Golden was with The Upjohn Company. He received his MS in Analytical Chemistry from the University of Georgia, Athens.

William Picht, Jr.

Vice President, Finance and Administration

William Picht has over 15 years of experience in finance, marketing analytics and strategy in the life sciences industry. Prior to joining Pearl in May 2008 as Senior Director, Finance, he held senior roles in strategic analysis, financial planning, and R&D finance at Nektar Therapeutics, most recently as Director, Finance. Prior to Nektar, he was a consultant with Objective Insights, Inc, where he assisted life sciences companies with new product assessment and developed forecasting and portfolio planning software. Mr. Picht began his career at Syntex Corporation in finance and marketing research. He has an M.B.A from San Jose State University, and a B.A. in Economics from the University of Notre Dame.

Chadwick J. Orevillo, MPH

Senior Director and Head of Clinical Operations

Chadwick J. Orevillo has over 16 years of global pharmaceutical research and development experience in all phases of pre-clinical and clinical drug development. Prior to joining Pearl Therapeutics, he was a Director of Clinical Development and Respiratory Program Section Leader at Novartis. In this role, he was responsible for MFF (mometasone furoate/formoterol fumarate MDI, a joint collaboration with Schering-Plough) and Foradil® where he managed a team of clinical professionals located in the US and abroad. Preceding this role at Novartis he was a Global Clinical Program Leader responsible for the integration of the inhaled tobramycin development programs from Chiron after Novartis’ acquisition of the company, and also worked on a number of other inhaled product development programs for the treatment of asthma and COPD during his tenure. Earlier in his career he worked on various clinical and pre-clinical development programs at Pharmacia, Kendle International, Merck, and Pharmaco-LSR. Mr. Orevillo received his Master of Public Health degree from Tulane University and a B.S. in Biological Sciences from William Paterson University.